10:34 AM
 | 
Jul 10, 2018
 |  BC Extra  |  Clinical News

Latest luspatercept readout a second win for Acceleron, Celgene

Acceleron Pharma Inc. (NASDAQ:XLRN) climbed $1.36 to $48.76 Tuesday after it and partner Celgene Corp. (NASDAQ:CELG) said luspatercept (ACE-536) met the primary endpoint in the Phase III BELIEVE study to treat beta-thalassemia. The companies are planning regulatory submissions for the candidate in the U.S. and EU in 1H19.

The results come less than two weeks after the partners said luspatercept met the primary endpoint in another Phase III trial, MEDALIST, to treat myelodysplastic syndrome (MDS). Celgene and Acceleron are also planning U.S. and EU submissions in that indication in 1H19 (see...

Read the full 435 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >